Navigation Links
FDA Mulls Direct Pharmacist-to-Patient Drug Sales
Date:11/13/2007

'Behind-the-counter' dispensing means doctor's prescriptions wouldn't be needed for certain meds

TUESDAY, Nov. 13 (HealthDay News) -- Experts at the U.S. Food and Drug Administration are meeting Wednesday to hear arguments on whether or not pharmacists might someday bypass doctors and directly provide consumers with certain drugs that now require a prescription.

If this plan were to go ahead, it would create a new class of drugs that could be sold by pharmacists "behind-the-counter." Such drugs might include birth control pills, cholesterol drugs and migraine medicine, experts said. Their sales would require that patients discuss these purchases with the pharmacist first.

"We believe having certain drugs behind the counter, but available only after a consultation with a pharmacist, could significantly increase patient access," Ilisa Bernstein, the FDA's director of pharmacy affairs, told the Los Angeles Times.

Wednesday's hearing marks another chapter in the behind-the-counter saga. In 2005, the agency rejected a proposal to allow the cholesterol-lowering drug Mevacor to be sold without a prescription. At the time, however, some of the FDA's scientific advisers said it might be possible for pharmacists to sell the drug if they could help select which customers bought the pills.

But the issue finds arguments both pro and con.

Several industry groups support the creation of this new method of providing medicine to patients.

"This new class could translate into increased access for patients while providing additional safeguards through pharmacist interventions that would better ensure appropriate medication use," John A. Gans, Pharm.D., CEO of the American Pharmacists Association, said in a prepared statement.

"Pharmacists' medication expertise and accessibility place them in a unique position to provide the oversight that would benefit patients taking certain products," he added.

But the country's largest organization representing physicians, the American Medical Association, does not endorse the plan.

"We are opposed to it for a variety of reasons," said Joseph Cranston, AMA's director of Science, Research, and Technology. "First of all, we don't think FDA has the legal authority to establish it without legislation."

His group also does not believe there's even a need for this new form of dispensing medicine, Cranston said. "Most importantly, we are most concerned about the types of drugs that could be moved to this class, particularly for patients with chronic illnesses, where it is critical that there be diagnosis and management by a physician," he added.

Cranston believes the move toward behind-the-counter sales is fueled by the pharmacy and pharmaceutical industries, which he believes would see more sales -- especially of older drugs or drugs that have gone off patent.

There are several reasons that the FDA is considering the proposal. Among these is the assertion that the plan improves pharmacist interaction with patients and ensures safe and effective use of drugs requiring a prescription.

In addition, allowing certain drugs to be sold without a prescription might boost patient access to medications that are typically underused, especially by patients who don't have health insurance, experts said.

Variations of behind-the counter drug sales already exist in other countries, including Australia, Canada, France, New Zealand, the United Kingdom, Denmark, Germany, Italy, the Netherlands, Sweden, and Switzerland, according to the FDA.

The medications that these countries allow to be sold by pharmacists without a prescription are those that treat a self-diagnosed condition -- with the help of a pharmacist. Drugs with few side effects and with a low probability for overdose are also often included in behind-the-counter dispensing, the FDA noted.

Some countries require that the pharmacist ensure that the patient meets certain criteria before dispensing the drug, the agency said. Pharmacists are also asked to provide customers with education on the proper use of the drug and to monitor patient outcomes, according to the FDA.

A major consumer group sided with the AMA against behind-the-counter sales.

"The idea of behind-the-counter-drugs is not new," Dr. Sidney Wolfe, director of the Health Research Group at Washington, D.C.-based Public Citizen, said in a prepared statement. "The FDA has previously considered creating a third class of drugs -- an intermediate step between prescription medications and over-the-counter drugs -- but has not supported the idea, citing the need for more research. That need still exists today," he added.

One government study found that before such a program could be instituted, a number of questions needed to be answered, Wolfe noted. Those included questions as to the risks of inadequate counseling by pharmacists, cost, and the usefulness and logistics of adding this third layer of distribution.

"There's little evidence that these concerns have been addressed," Wolfe said. "Many questions still remain unanswered -- Will pharmacists have the training and the time to explain the drugs and side effects to patients? Who will pay for that training? Will this third class pull more from drugs currently sold over-the-counter or from those requiring a prescription? And will drug companies push to get their current prescription products into this class to avoid regulation?"

Finally, Wolfe said, "Will behind-the-counter availability effectively turn the drug store counter into a vending machine, free from doctors' oversight? The FDA needs to put more research behind the plan before it tells Congress it's OK to put more drugs behind the counter," he said.

But one New York City pharmacist believes those fears are overblown.

"It will be a great opportunity for patients to interact more with their pharmacists," said Catherine Tom-Revzon, a clinical pharmacy manager at the Children's Hospital at Montefiore Medical Center. "Pharmacists do have a wealth of knowledge to offer in regards to the proper use of medications and whether the drug that will be behind-the-counter will interact with the current medications that patients are on," she said.

In addition, Tom-Revzon believes the proposal will give pharmacists the ability to monitor the effectiveness of a medication and then change drugs and doses as needed. "It's a great opportunity for a pharmacist to work more closely with patients and prescribers," she said.

Some drugs may require that patients provide proof that the drug is needed, Tom-Revzon noted. Pharmacists may also ask patients for specific blood tests before selling a particular drug to be sure the drug is appropriate, she said. Pharmacists are trained to read such tests, Tom-Revzon noted.

More information

For more on drug regulation, visit the U.S. Food and Drug Administration.



SOURCES: U.S. Food and Drug Administration, Federal Register notice; Joseph Cranston, Ph.D., director, Science, Research, and Technology, American Medical Association, Chicago; Public Citizen, press statement; Oct. 5, 2007, Los Angeles Times; American Pharmacists Association, press statement; Catherine Tom-Revzon, Pharm.D., clinical pharmacy manager, Children's Hospital, Montefiore Medical Center, New York City


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Panel Mulls Ban on Kids Cold Medicines
2. Direct Anesthetic Infusion Helps Colorectal Cancer Patients
3. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
4. National Association of Subrogation Professionals (NASP), the Largest Insurance Subrogation Association in the World - Announced Today that Leslie Wiernik has Joined the Organization as Director of Education
5. HealthInsuranceFinders.com Launches Video Contest for Young Directors
6. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
7. Coalition for Pulmonary Fibrosis Launches Aggressive Ad Campaign Directed at United States Congress
8. Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders
9. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. Fitness Champion Natalie Waples to be Spokesperson for Natural Nutrition International Direct Marketing Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Mulls Direct Pharmacist-to-Patient Drug Sales
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... simulation -centric training, today announced the launch of a new research study, The ... the skills needed to execute that strategy, and the actual success of achieving ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... announce that for a second year in a row; they are the recipient ... designers in the industry voted on the award at Design Connections 2017. Top ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
(Date:3/27/2017)... Texas , March 27, 2017   Genprex, Inc. , ... that Julien Pham , MD, the Company,s Chief Operating Officer, ... investor conferences. Sachs 5th Annual Cancer BioPartnering & ... New York, NY ... BioCentury 24th Annual Future Leaders in ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators ... $724 million by 2022, growing at a CAGR of 3.6% during the forecast ... ... Allied Market Research Logo ...
Breaking Medicine Technology: